FNA vs. PRCT, NVST, IRTC, NVCR, LIVN, ENOV, WRBY, TNDM, LMAT, and CNMD
Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), LeMaitre Vascular (LMAT), and CONMED (CNMD). These companies are all part of the "medical equipment" industry.
Paragon 28 vs.
PROCEPT BioRobotics (NASDAQ:PRCT) and Paragon 28 (NYSE:FNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
In the previous week, Paragon 28 had 26 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 29 mentions for Paragon 28 and 3 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 0.79 beat Paragon 28's score of 0.23 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.
Paragon 28 has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
Paragon 28 has a net margin of -25.31% compared to PROCEPT BioRobotics' net margin of -50.07%. Paragon 28's return on equity of -37.90% beat PROCEPT BioRobotics' return on equity.
PROCEPT BioRobotics currently has a consensus price target of $97.86, suggesting a potential upside of 34.98%. Paragon 28 has a consensus price target of $14.60, suggesting a potential upside of 12.09%. Given PROCEPT BioRobotics' stronger consensus rating and higher probable upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Paragon 28.
PROCEPT BioRobotics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
PROCEPT BioRobotics received 3 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 76.09% of users gave Paragon 28 an outperform vote while only 67.86% of users gave PROCEPT BioRobotics an outperform vote.
89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 17.4% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 15.3% of Paragon 28 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Paragon 28 beats PROCEPT BioRobotics on 10 of the 18 factors compared between the two stocks.
Get Paragon 28 News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Paragon 28 Competitors List
Related Companies and Tools
This page (NYSE:FNA) was last updated on 2/1/2025 by MarketBeat.com Staff
